Voltage-gated sodium channels in cancer. The biology, explained for non-scientists.

A patient called me last week. Her oncologist had mentioned voltage-gated sodium channels and Targeted Osmotic Lysis as one of the investigational paths she might consider. She asked me to explain it without the jargon.

This issue is that explanation. If you have a cancer with poor remaining options, or if you advise someone who does, you should understand at least the outline of this biology. It is the foundation under one of the more interesting investigational platforms in oncology.

What voltage-gated sodium channels are

Every cell in your body maintains an electrical gradient across its membrane. Inside the cell is negative relative to outside. The cell does that by pumping sodium out and potassium in. The pump that does this work is called the sodium-potassium ATPase.

When a cell needs to do work that requires letting sodium back in, it opens specialized doorways called voltage-gated sodium channels. These channels are why your neurons fire, why your heart beats in rhythm, and why your muscles contract. Sodium rushes in, the cell does its job, and the pump restores the gradient afterward.

Healthy adult cells outside nerve, heart, and muscle tissue express very few of these sodium channels. They do not need them. The pump handles the gradient, and life proceeds.

What goes wrong in cancer

When a cancer cell becomes metastatic, something unusual happens. The cell begins expressing voltage-gated sodium channels at levels 10 to 50 times higher than the surrounding tissue. This has been documented in breast cancer, prostate cancer, colon cancer, gastric cancer, lung cancer, cervical cancer, head and neck cancer, brain cancer, and several others.

Why? The current theory is that the channels help the cancer cell migrate. Metastasis requires the cell to detach from its original tissue, reshape itself, push through the surrounding matrix, and enter the bloodstream. Sodium channel activity supports several of those steps. The cancer turns the channels on because they help it spread.

This is one of the few biological markers that genuinely distinguishes aggressive cancer cells from the healthy cells around them. Most chemotherapy targets fast-dividing cells in general. That is why chemo also damages hair follicles, gut lining, and bone marrow. They divide fast too. Sodium channel over-expression is different. It is specific to the aggressive cancer cells. Healthy cells around the tumor do not have it.

What Targeted Osmotic Lysis does

The investigational platform called Targeted Osmotic Lysis exploits this difference. The mechanism has three steps.

Step one. A small dose of a cardiac glycoside, the same class of drugs used at much higher doses for heart failure, blocks the sodium-potassium ATPase pump on all cells in the treatment field. The pump that restores the gradient is now off.

Step two. A short pulsed electric field stimulates the voltage-gated sodium channels to open. Healthy cells do not have many channels, so not much happens to them. The cancer cells have 10 to 50 times more channels, so a flood of sodium ions enters them.

Step three. Water follows the sodium into the cell by osmotic pressure. The cell swells. The pump that would normally restore balance is blocked. The cell ruptures. This is lysis. The cancer cell dies.

The selectivity comes from the channel density difference. The pump block hits everyone equally. The electric field hits everyone equally. The amount of damage hits everyone unequally, because the cancer cell has so many more channels that it takes the brunt of the sodium influx. Surrounding tissue recovers when the drug wears off. The aggressive cancer cells do not.

What this is and is not

Targeted Osmotic Lysis is investigational. It is not FDA-approved for any indication. It has been studied in published preclinical work and in early clinical case reports under regulatory frameworks that permit experimental use in patients who have exhausted standard therapies.

Access to the platform exists through clinical trial enrollment listed at ClinicalTrials.gov, FDA Expanded Access under 21 CFR Part 312 Subpart I, the federal Right to Try Act of 2018, and authorized international partner sites in Mexico under COFEPRIS authority and Australia under the TGA Special Access Scheme.

The mechanism is explained at https://fixcancer.org. Per-cancer eligibility frameworks are at https://fixcancers.com. Both are independent reference sites built around the science, not selling pages for a clinic.

What patients and families should understand

This is not a cure. No serious researcher in oncology talks about cures with metastatic disease. This is one mechanism among many being studied for cancers that have outrun standard therapy.

It is also not snake oil. The voltage-gated sodium channel biology is published in mainstream cancer journals. The platform is in active clinical investigation under recognized regulatory frameworks. The mechanism is testable, falsifiable, and grounded in molecular biology that any oncologist can verify.

If you or someone you love is considering TOL, do three things. Get the complete medical record from your treating oncologist. Bring the case to an NCI-designated comprehensive cancer center for a second opinion, with the molecular profile of your tumor in hand. Then evaluate whether TOL or any other investigational platform fits the specific biology of your disease.

The biology is real. The platform is investigational. The system rewards patients who walk into the conversation organized.

Andrew J. Hillman writes The Hillman Letter for operators, investors, and patient families navigating advanced disease. He is the principal of Hillman Ventures, a Dallas-based family office investing in frontier biotech. More at https://andrew-hillman.com.